Edwards Lifesciences' Progress Data Unlikely to Expand TAVR Market, RBC Says

11:49 AM EST, 11/03/2026 (MT Newswires) -- Edwards Lifesciences' (EW) Progress trial is unlikely to meaningfully expand the market for transcatheter aortic valve replacement, or TAVR, while separate tricuspid data reinforce the expectation that repair and replacement procedures will coexist, RBC Capital Markets said. The firm's key opinion leader said the absence of a mortality benefit in the trial was expected, while a directionally unfavorable mortality signal raises some concerns. The results are unlikely to change current treatment patterns, according to the note Monday. The KOL expects overall transcatheter aortic valve replacement procedures to grow 15% to 20% in 2027, driven by an aging population, improved diagnosis and the early use of replacement valves in patients who have previously received one. In tricuspid procedures, the physician expects repair and replacement to maintain an approximately 50/50 market split, with procedure volumes growing about 5% annually. RBC reiterated its outperform rating and $110 price target on Edwards Lifesciences. The company's shares were up nearly 3% in Tuesday trading. Price: 95.98, Change: +2.71, Percent Change: +2.91